At present, the main drugs for patients with advanced liver cancer are several targeted drugs: first, sorafenib; second, regorafenib; third, lenvatinib, all of which are targeted drugs against tumor angiogenesis. The latest developed one is sorafenib, which can extend the overall survival time of patients to about 1 year. Later, regorafenib or lenvatinib was developed for second-line treatment after the progression of sorafenib. Currently, the main indications of targeted drugs are advanced hepatocellular carcinoma, which can be used on the condition of liver function ChiLdA grade or B grade with good general status, that is, patients do not have obvious ascites before Use of targeted drugs. Other advanced hepatocellular carcinoma drugs, including albumin or liver protection drugs, antiviral drugs, are needed in advanced hepatocellular carcinoma, and other drugs such as proprietary Chinese medicine can also be used for advanced hepatocellular carcinoma.